BioMarin expects $3.2 billion in 2025 revenue, ROCTAVIAN write-down

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) disclosed preliminary financial results during a presentation at the J.P. Morgan Healthcare Conference on January 12, 2026.

The company estimates it generated approximately $3.2 billion in total revenues for 2025, based on unaudited preliminary results. VOXZOGO sales contributed approximately $920 million to the annual revenue figure.

BioMarin expects to record an asset write-down related to ROCTAVIAN in the fourth quarter of 2025 ranging from $230 million to $260 million. The write-down will reduce the company's Non-GAAP income and Non-GAAP diluted earnings per share by approximately $120 million to $125 million, or $0.60 to $0.64 per share, based on approximately 200 million weighted-average diluted shares outstanding.

The company stated that excluding the asset write-down impact, its 2025 full-year financial guidance for Non-GAAP diluted earnings per share remains unchanged from guidance provided on October 27, 2025.

The information was disclosed during BioMarin's business update presentation at the healthcare conference.

You May Also Be Interested In

• Two Harbors rejects UWM Holdings lawsuit amid pending CrossCountry deal
• JPMorgan Upgrades Multi Commodity Exchange of India Ltd (MCX:IN) to Overweight
• Deutsche Bank Downgrades AtaiBeckley Inc (ATAI) to Hold